GB0901411D0 - Treatment - Google Patents

Treatment

Info

Publication number
GB0901411D0
GB0901411D0 GBGB0901411.9A GB0901411A GB0901411D0 GB 0901411 D0 GB0901411 D0 GB 0901411D0 GB 0901411 A GB0901411 A GB 0901411A GB 0901411 D0 GB0901411 D0 GB 0901411D0
Authority
GB
United Kingdom
Prior art keywords
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0901411.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UK Secretary of State for Defence
Original Assignee
UK Secretary of State for Defence
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UK Secretary of State for Defence filed Critical UK Secretary of State for Defence
Priority to GBGB0901411.9A priority Critical patent/GB0901411D0/en
Publication of GB0901411D0 publication Critical patent/GB0901411D0/en
Priority to PCT/GB2010/000153 priority patent/WO2010086617A2/en
Priority to GB1001521A priority patent/GB2467437A/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB0901411.9A 2009-01-29 2009-01-29 Treatment Ceased GB0901411D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB0901411.9A GB0901411D0 (en) 2009-01-29 2009-01-29 Treatment
PCT/GB2010/000153 WO2010086617A2 (en) 2009-01-29 2010-01-29 Treatment
GB1001521A GB2467437A (en) 2009-01-29 2010-01-29 Phosphoantigen for use in the treatment of tularemia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0901411.9A GB0901411D0 (en) 2009-01-29 2009-01-29 Treatment

Publications (1)

Publication Number Publication Date
GB0901411D0 true GB0901411D0 (en) 2009-03-11

Family

ID=40469217

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB0901411.9A Ceased GB0901411D0 (en) 2009-01-29 2009-01-29 Treatment
GB1001521A Withdrawn GB2467437A (en) 2009-01-29 2010-01-29 Phosphoantigen for use in the treatment of tularemia

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB1001521A Withdrawn GB2467437A (en) 2009-01-29 2010-01-29 Phosphoantigen for use in the treatment of tularemia

Country Status (2)

Country Link
GB (2) GB0901411D0 (en)
WO (1) WO2010086617A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0212666D0 (en) 2002-05-31 2002-07-10 Secr Defence Immunogenic sequences
EP2040744B1 (en) 2006-07-25 2016-03-09 The Secretary of State for Defence Live vaccine strains of francisella
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5666A (en) 1848-07-11 Machinery for sawing irregular shapes
US153A (en) 1837-03-25 Peters
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
SE8205892D0 (en) 1982-10-18 1982-10-18 Bror Morein IMMUNOGENT MEMBRANE PROTEIN COMPLEX, SET FOR PREPARATION AND USE THEREOF
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
JP2851288B2 (en) 1987-06-05 1999-01-27 アメリカ合衆国 Autocrine motility factors in cancer diagnosis and management
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5308854A (en) 1990-06-18 1994-05-03 Merck & Co., Inc. Inhibitors of HIV reverse transcriptase
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
US5192668A (en) 1990-10-11 1993-03-09 Merck & Co., Inc. Synthesis of protease inhibitor
US5187074A (en) 1990-10-11 1993-02-16 Merck & Co., Inc. Method of hydroxylation with ATCC 55086
WO1993008184A1 (en) 1991-10-23 1993-04-29 Merck & Co., Inc. Hiv protease inhibitors
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
SG90042A1 (en) 1992-06-25 2002-07-23 Smithkline Beecham Biolog Vaccine composition containing adjuvants
US5665720A (en) 1992-08-07 1997-09-09 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
WO1994021292A1 (en) 1993-03-23 1994-09-29 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
WO1995010281A1 (en) 1993-10-13 1995-04-20 Merck & Co., Inc. Combination therapy for hiv infection
DK0729473T3 (en) 1993-11-17 2000-10-30 Deutsche Om Arzneimittel Gmbh Glucosamine disaccharides, process for their preparation pharmaceutical composition and their use
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5476874A (en) 1994-06-22 1995-12-19 Merck & Co., Inc. New HIV protease inhibitors
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
UA56132C2 (en) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine
US5846978A (en) 1996-05-02 1998-12-08 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
HUP0102332A3 (en) 1998-06-08 2002-11-28 Sca Emballage France Fast flattening packaging
EE04489B1 (en) 1998-06-30 2005-06-15 Om Pharma Acyl pseudodipeptides, process for their preparation and pharmaceutical compositions containing them
FR2782721B1 (en) * 1998-09-01 2000-11-03 Inst Nat Sante Rech Med NOVEL PHOSPHOHALOHYDRIN COMPOUNDS, MANUFACTURING METHOD AND APPLICATIONS
AU764969B2 (en) 1999-04-19 2003-09-04 Smithkline Beecham Biologicals (Sa) Vaccines
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
AU1581400A (en) 1999-12-22 2001-07-03 Om Pharma Acyl pseudopeptides bearing a functionalised auxiliary spacer
EP1408984B1 (en) * 2001-07-20 2008-10-22 BioAgency AG Organo-phosphorous compounds for activating gamma/delta t cells
US20070025960A1 (en) * 2003-05-16 2007-02-01 University Of Maryland Biotechnology Institute Bisphosphonates for prophylaxis and therapy against bioterrorism agents
WO2005102385A1 (en) * 2004-04-26 2005-11-03 Innate Pharma Adjuvant composition and methods for its use
WO2006067635A2 (en) * 2004-12-20 2006-06-29 Innate Pharma S.A. USE OF Ϝδ T LYMPHOCYTE ACTIVATORS AS VACCINE ADJUVANT
KR20070113314A (en) * 2005-03-22 2007-11-28 이나뜨 파르마 NEW CLASS OF gamma;delta; T CELLS ACTIVATORS AND USE THEREOF
WO2009131730A2 (en) * 2008-01-31 2009-10-29 University Of Iowa Research Foundation IMMUNOGENIC COMPOSITIONS FOR ACTIVATING γδ T CELLS
EP2123285A1 (en) * 2008-05-21 2009-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Nucleosidic phosphoantigens for use in VGAMMA9DELTA2 T cell-mediated therapy

Also Published As

Publication number Publication date
GB2467437A (en) 2010-08-04
WO2010086617A2 (en) 2010-08-05
GB201001521D0 (en) 2010-03-17
WO2010086617A3 (en) 2010-09-16

Similar Documents

Publication Publication Date Title
HK1175476A1 (en) Cancer treatment
PL2652193T3 (en) Treatment
IL213619A0 (en) Treatment
GB0802116D0 (en) Treatment
GB0920112D0 (en) Treatment device
GB0822011D0 (en) Treatment
IL217492A0 (en) Treatment method
PT2437739E (en) Glomerulonephritis treatment
IL214133A0 (en) Skin treatment
GB0811992D0 (en) Treatment
GB0900599D0 (en) Treatment
GB201013898D0 (en) Well treatment
GB201013573D0 (en) Treatment
GB201001521D0 (en) Treatment
GB0913968D0 (en) Treatment
PL2263454T3 (en) Treatment composition
GB0916997D0 (en) Combination therapy
GB0820972D0 (en) Treatment
GB0805912D0 (en) Treatment
GB201014097D0 (en) Treatment
GB0907973D0 (en) Combination therapy
GB201001517D0 (en) Treatment
GB0914581D0 (en) Well treatment
GB0916542D0 (en) Well treatment
GB0915045D0 (en) Treatment system

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)